<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC6156540/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Clinical trials employing RNA vaccines in pandemic settings.</p>
 </caption>
 <thead>
  <tr>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-0-.">
    <b>Study start</b>
   </th>
   <th valign="top" align="center" rowspan="1" colspan="1" id="0-1-.">
    <b>
     <i>N</i>
    </b>
   </th>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-2-.">
    <b>Vaccine and delivery</b>
   </th>
   <th valign="top" align="left" rowspan="1" colspan="1" id="0-3-.">
    <b>Outcome</b>
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td valign="top" align="left" colspan="2" rowspan="1">
    <b>NCT03014089</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>ZIKA</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I/II</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Dec 2016</td>
   <td valign="top" align="center" rowspan="1" colspan="1">90</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>mRNA 1325</b>, modified nucleotides; LNP-formulated, Antigen: prM-E polyprotein 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">Results pending; estimated primary completion date in Sept 2018</td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="2" rowspan="1">
    <b>NCT03076385</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>INFLUENZA H10N8</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Dec 2015</td>
   <td valign="top" align="center" rowspan="1" colspan="1">201</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>mRNA 1851</b>, modified nucleotides; LNP-formulated, Antigen: HA of H10N8 A/Jiangxi-Donghu/346/2013 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">Interim results published for 100 μg IM ( 
    <i>N</i> = 23) vs. placebo ( 
    <i>N</i> = 8) 
    <br/>
    <b>Safety:</b> acceptable safety profile 
    <br/>
    <b>Immunogenicity:</b>
    <br/> - HI titers ≥40 in 100% (23/23) of subjects at day 43 
    <br/> - MN ≥20 in 87% (20/23) at day 43 
   </td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="2" rowspan="1">
    <b>NCT03345043</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>INFLUENZA H7N9</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">May 2016</td>
   <td valign="top" align="center" rowspan="1" colspan="1">156</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>mRNA 1440</b>, modified nucleotides; LNP-formulated, Antigen: HA of H7N9 A/Anhui/1/2013 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">Results pending; estimated primary completion date in Sept 2018</td>
  </tr>
  <tr style="border-top: thin solid #000000;">
   <td valign="top" align="left" colspan="2" rowspan="1">
    <b>NCT03325075</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>CHIKUNGUNYA</b>
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>Phase I</b>
   </td>
  </tr>
  <tr>
   <td valign="top" align="left" rowspan="1" colspan="1">Aug 2017</td>
   <td valign="top" align="center" rowspan="1" colspan="1">60</td>
   <td valign="top" align="left" rowspan="1" colspan="1">
    <b>mRNA 1388</b>, modified nucleotides; LNP-formulated Antigen: structural polyprotein 
   </td>
   <td valign="top" align="left" rowspan="1" colspan="1">Results pending; estimated primary completion date in Sept 2019</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>This table exclusively lists clinical trials discussed in the text; prM-E, preMembrane-Envelope; HA, Hemagglutinin; HI, hemagglutination inhibition; MN, microneutralization titers; N, number of study participants; IM, intramuscular; ID, intradermal; LNP, lipid nanoparticle</i>. 
  </p>
 </tfoot>
</table>
